Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London

12.03.08 - 12:35 ... source : Crucell

... London, March 12, 2008 - Dutch biopharma company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) today presents an update on the company's performance, strategy for growth acceleration and a review of the company's pipeline at a meeting for investors and analysts in London. A live audio webcast of the meeting, together with the program and slides of all presentations, will be available on Crucell's website at www.crucell.com. Presentations given by senior management and program managers outline a compelling case for investment in Crucell, based on significant solid growth of the company's vaccines business. Furthermore Crucell enjoys a pipeline of multiple products tailored to address major threats to health and well-being worldwide as well as strong partnerships in vaccine and antibody research. Crucell's portfolio of unique technologies generating licen ...» Next (HTML)